Management of restless legs syndrome by the partial D2-agonist terguride
Language English Country Netherlands Media print
Document type Clinical Trial, Journal Article
PubMed
14592288
DOI
10.1016/s1389-9457(03)00165-5
PII: S1389945703001655
Knihovny.cz E-resources
- MeSH
- Dopamine Agonists administration & dosage therapeutic use MeSH
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Lisuride administration & dosage analogs & derivatives therapeutic use MeSH
- Receptors, Dopamine D2 agonists MeSH
- Self-Assessment MeSH
- Aged MeSH
- Sleep MeSH
- Sleep Stages drug effects MeSH
- Restless Legs Syndrome drug therapy physiopathology MeSH
- Treatment Outcome MeSH
- Check Tag
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Clinical Trial MeSH
- Names of Substances
- Dopamine Agonists MeSH
- dironyl MeSH Browser
- Lisuride MeSH
- Receptors, Dopamine D2 MeSH
BACKGROUND: Terguride as a partial D2-receptors agonist seems suitable for treatment of restless legs syndrome (RLS). METHODS: Nine RLS patients without previous dopaminergic therapy received a daily dose of terguride (0.25 mg) 29.9+/-16.9 (SD) days. RESULTS: Two patients enrolled in the study failed to turn up for a successive check up. The seven subjects who were re-examined complied with the therapy. Their RLS symptoms improved (as measured on the International RLS intensity scale), decreasing from 24.3+/-5.3 to 14+/-4.7 (p=0.014). However, the terguride treatment did not significantly alter the daytime sleepiness or the subjective duration of nocturnal sleep. The daily dose was doubled in three patients who reported insufficient RLS improvement. One of the three patients later reported augmentation.
References provided by Crossref.org
